Retractable Technologies Inc (RVP)

[Enterprising Investor]

Hopefully, you are still holding.

[fung_derf]

Not blaming you, but you were the reason I bought shares....you were doing pretty well up until this one.

[Enterprising Investor]

Hopefully, no one thinks it was me.

However, I do envision this company be taken private or bought out one day. Shaw continues to buy shares almost every day. Eventually, Shaw will need an exit strategy.

[elcheepo]

Typical crap stock

[fung_derf]

I wonder who started the positive rumors on 3/15?

[JJSeabrook]

Wonder if Shaw will keep buying now that the 5th Circuit has ruled against RVP? Should be interesting to see. If he does, then something else is in the works rather than his possibly banking on winning at the 5th Circuit. I hope his buys keep going through.

[JJSeabrook]

Trading has resumed. Currently down 5.99%. The decision actually came out yesterday.

[JJSeabrook]

In short, it says RVP won't get a dime from BD.

[JJSeabrook]

Here's a link to the 5th Circuit decision: www.ca5.uscourts.gov/opinions/pub/17/17-40960-CV0.pdf

[JJSeabrook]

Retractable Technologies, Inc. Reports on Fifth Circuit Opinion
March 27, 2019 11:00 AM Eastern Daylight Time

LITTLE ELM, Texas--(BUSINESS WIRE)--Retractable Technologies, Inc. (“Retractable”) (NYSE American: RVP) announced today that on March 26, 2019, the Fifth Circuit Court of Appeals affirmed the district court’s finding which had determined that neither disgorgement of profits nor further injunctive relief should be granted to Retractable in its case against Becton, Dickinson and Company (“BD”), despite finding that BD falsely advertised its products for years. Retractable is evaluating this ruling and conferring with legal counsel regarding possible future action.

Retractable manufactures and markets VanishPoint® and Patient Safe® safety medical products and the EasyPoint® needle. The VanishPoint® syringe, blood collection, and IV catheter products are designed to prevent needlestick injuries and product reuse by retracting the needle directly from the patient, effectively reducing exposure to the contaminated needle. Patient Safe® syringes are uniquely designed to reduce the risk of bloodstream infections resulting from catheter hub contamination. The EasyPoint® is a retractable needle that can be used with luer lock syringes, luer slip syringes, and prefilled syringes to give injections. The EasyPoint® needle also can be used to aspirate fluids and for blood collection. Retractable's products are distributed by various specialty and general line distributors.

For more information on Retractable, visit its website at www.retractable.com.

Forward-looking statements in this press release are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995 and reflect Retractable's current views with respect to future events. Retractable believes that the expectations reflected in such forward-looking statements are accurate. However, Retractable cannot assure you that such expectations will materialize. Actual future performance could differ materially from such statements.

Factors that could cause or contribute to such differences include, but are not limited to: potential tariffs, Retractable's ability to maintain liquidity; Retractable's maintenance of patent protection; the impact of current and future Court decisions regarding current litigation; Retractable's ability to maintain favorable third party manufacturing and supplier arrangements and relationships; foreign trade risk; Retractable's ability to quickly increase capacity in response to an increase in demand; Retractable's ability to access the market; Retractable's ability to maintain or lower production costs; Retractable's ability to continue to finance research and development as well as operations and expansion of production; the impact of larger market players, specifically BD, in providing devices to the safety market; and other risks and uncertainties that are detailed from time to time in Retractable's periodic reports filed with the U.S. Securities and Exchange Commission.

Contacts

Retractable Technologies, Inc.
Michele M. Larios, 888-806-2626 or 972-294-1010
Vice President, General Counsel, and Secretary

[JJSeabrook]

HALTED PENDING NEWS!

[Enterprising Investor]

Buyout coming?

[oilin07]

Heading to $2

[elcheepo]

Yes, I know he has been buying , and I wish I bought as many as he did, but I was wondering if there was anything more that is upcoming and driving this

[fung_derf]

Retractable Needle Safety Syringes Market, 2025

PR Newswire
12:15 PM (UTC-05:00) Eastern Time (US & Canada) Feb 06, 2018
For best results when printing this announcement, please click on link below:
http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20180206:nPreY99Vca

Retractable Needle Safety Syringes Market, 2025
PR Newswire

DUBLIN, Feb. 6, 2018

DUBLIN, Feb. 6, 2018 /PRNewswire/ --

The "Global Retractable Needle Safety Syringes Market Size, Market Share,
Application Analysis, Regional Outlook, Growth Trends, Key Players,
Competitive Strategies and Forecasts, 2017 to 2025"
(https://www.researchandmarkets.com/research/88h3bg/retractable?w=5) report
has been added to ResearchAndMarkets.com's offering.

The global retractable needle safety syringes market was valued at US$ 1,345
Mn in 2016, and is expected to reach US$ 2,345.7 Mn by 2025, expanding at a
CAGR of 6.1% from 2017 to 2025

Market Insights

According to WHO studies, almost 16 billion injections are administered every
year; out of which a majority i.e. 90% is given in curative care. General
trend of unsafe syringe practice is observed all over the world, especially in
developing countries, which has led to transmission of infection amongst the
patient and healthcare professional. Though the exact data is not available
for disease burden associated with unsafe and reuse of syringe practices, but
it would lead to disease such as haemorrhagic fevers such as Ebola and Marburg
viruses, bacterial infection, malaria, and others. The WHO has set guidelines
for safe practice of syringe usage and developed a global campaign to promote
injection safety. These safety guidelines would help to protect health workers
against needle stick accidents and further exposure to infection. The
guidelines have also recommended the usage of new smart syringes that would
prevent reuse, urging countries to transition by 2020. Introduction of cost
effective safety engineered syringes would drive the growth of the retractable
needle safety syringes.

The global retractable needle safety syringes market is segmented by product
type into manual retractable syringes and automatic-retractable safety
syringes. Manual retractable syringes dominate the retractable needle safety
syringes, due to their wide usage and cost effectiveness. The market is also
segmented by end users into hospitals, clinics and ambulatory surgery centres.
Hospitals dominate the global retractable needle safety syringes market and is
rapidly growing with WHO guideline for usage of smart syringes

As of the current market scenario, North America dominated the global
retractable needle safety syringes market followed by Europe. Factors
contributing to the growth of North America includes government initiative and
regulation for safety practices, rise in incidence of needlestick injury and
enhanced safety needles. Asia Pacific is the fastest growing retractable
needle safety syringes market in forecast period.

Market Competition Assessment

Key players in the global retractable needle safety syringes market are Axel
Bio Corporation, Becton, Dickinson and Company, DMC Medical Limited, Globe
Medical Tech, Inc., Medtronic Plc, Medigard Limited, Retractable Technologies,
Inc., Smiths Medical, Sol-Millennium, UltiMed, Inc. and others.

Key Market Movements:
* Awareness about infection risk due to unsafe practices of syringe and its
reuse has led to usage of safety syringes by the healthcare workers to avoid
needle stick accidents
* WHO guidelines and recommendations for safety practice and usage of syringes
to protect health workers against accidental needle injury and subsequent
exposure to infection
Key Topics Covered:

Chapter 1. Preface
1.1. Report Scope and Description
1.2. Research Methodology

Chapter 2. Executive Summary
2.1. Global Retractable Needle Safety Syringes Market Portraiture
2.1.1. Global Retractable Needle Safety Syringes Market, by Product Type, 2016
2.1.2. Global Retractable Needle Safety Syringes Market, by `End Users, 2016
2.1.3. Global Retractable Needle Safety Syringes Market, by Geography, 2016

Chapter 3. Retractable Needle Safety Syringes Market: Market Dynamics and
Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.4.1. Attractive Investment Proposition, by Geography
3.5. Competitive Landscape
3.5.1. Competitive Landscape, by Key Players, 2016

Chapter 4. Global Retractable Needle Safety Syringes Market, by Product Type,
2015 - 2025 (US$ Mn)
4.1. Overview
4.2. Attractive Investment Proposition: Global Retractable Needle Safety
Syringes Market, by Product Type
4.3. Automatic Retractable syringes
4.4. Manual Retractable Safety Syringes

Chapter 5. Global Retractable Needle Safety Syringes Market, by End Users,
2015 - 2025 (US$ Mn)
5.1. Overview
5.2. Attractive Investment Proposition: Global Retractable Needle Safety
Syringes Market, by End Users
5.3. Hospitals
5.4. Clinics
5.5. Ambulatory Surgery Centers

Chapter 6. Global Retractable Needle Safety Syringes Market, by Geography,
2015 - 2025 (US$ Mn)

Chapter 7. Company Profiles
* Axel Bio Corporation
* Becton, Dickinson and Company
* DMC Medical Limited
* Globe Medical Tech, Inc.
* Medtronic Plc
* Medigard Limited
* Retractable Technologies, Inc.
* Smiths Medical
* Sol-Millennium, Inc.
* UltiMed, Inc.
For more information about this report visit
https://www.researchandmarkets.com/research/88h3bg/retractable?w=5

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[e-mail]

[fung_derf]

DJ Chmn Shaw Buys 11,612 Of Retractable Technologies Inc >RVP


11:18 AM (UTC-05:00) Eastern Time (US & Canada) Feb 20, 2018

SOURCE: Form 4

ISSUER: Retractable Technologies Inc
SYMBOL: RVP

FILER: Shaw Thomas J
TITLE: Chairman of the Board

DATE TRANSACTION SHARES PRICE VALUE
2/16/18 Purchase 11,612 $0.87 $10,157
(10b5-1 Plan Indicated)*

OWNERSHIP: 13,307,335 (Direct) 4,270,000 (Indirect)

* - A 10b5-1 plan enables an insider to establish a program to make trans-
actions according to an advance plan. Such a program allows an insider
to continue with planned transactions even if he or she comes into
possession of material non-public information.

The Form 4 is filed with the Securities and Exchange Commission by insiders
to report transactions in their companies' shares. Open market purchases
and sales must be reported within two business days of the transaction.

Insider Data Source: The Washington Service
([e-mail] or 301-913-5100)

(END) Dow Jones Newswires

February 20, 2018 11:18 ET (16:18 GMT)


NOCOPYRIGHT

[elcheepo]

What is driving this price rise?

[Saskey]

Woo! Mine just sold for $1 and I wasn't even expecting it yet! Musta just shot up out of the blue. Woo woo!

[WoollenBlock48]

Looking good! Let’s see that $1 test

[Saskey]

I wouldn't even begin to speculate on their intentions. But you are right, you don't often see good ones behind the scenes, at least not good for shareholders. I put more stock in chart movement, history of splits, short history vs. long history, odds of bouncing to my sell point, and other factors

[akamaii]

I’ve read the co files it’s just simple instead doing a shelf insiders loading at these levels these guys Habe good intentions you don’t see that now adays

[Saskey]

If you scroll back through the message board, people have speculated

[akamaii]

New here but I’m gonna give this a month here what’s the story with Shawn keeps buying

[akamaii]

I’m in let’s go

[Saskey]

2/1 Shaw's back! With a buy on 1/30.

[Saskey]

Did the autobuys stop? Shaw's last autobuy was on 1/16, thirteen days ago.

[Saskey]

Slow but steady climb since Aug/Sep 2016. And Shaw is continuing to auto-buy.

[upper11]

http://stockcharts.com/h-sc/ui?s=RVP&p=D&b=5&g=0&id=p04644058220
I think it’s ready

[Saskey]

Shaw's latest autobuys: 12/5, 12/6, 12/7, 12/11, 12/14, 12/15.

[Wildbilly]

Looking good, way to stick with it.

[Saskey]

Shaw still going strong. Still has his autobuys set. 11/27, 11/28, 11/29, 11/30, 12/1, and 12/4 adding stock.

[Saskey]

They've been around awhile with ups and downs. But even in the downs, they've never done an R/S. Right now they're about as low as they've ever been. They hit bottom one time before in 2009, and then started climbing up over the course of the next six years to hit $5.70 in 2015 from the .43 of 2009.

After that it went down again. I believe it will go back up. I'm not planning to stick around for six years looking for the great heights. I'll be perfectly happy to hold out for a few dimes more per share :D

[Wildbilly]

Just a drive by observation, your post caught my attention.

Up from here off this consolidation seems a decent bet after the year they've had starting Dec. '16.

[Saskey]

He kicked off 2017 by buying 2 million shares in January. And another 1 million on August 23. After that he set it up to automatically buy shares, although the amounts vary radically. Starting October 23, it looks as though he's buying in every single day, or close to it.

As to his motives, it's pure speculation.

I'm speculating on a profit from this stock. Your results may differ

[Wildbilly]

All of these buys since January

have been classified as "Voting or Investment Control(3)", potential voting rights and de-facto control or Tenure voting, greater than one share one vote. Often used to hold off hostile takeovers and also used in ways that are not shareholder friendly.

Not all insider buying is a 'happy clappy' affair and should be viewed with eyes wide open ...as usual.

[Saskey]

11/17: More Shaw buys. On 11/13, 11/14, 11/16.

[Saskey]

11/10: Shaw buys again! More buys on 11/9 and 11/10.

[upper11]

I’m loving the buys

[Saskey]

11/7: Thomas Shaw buys again! More insider buys on 11/6 and 11/7. He's not buying all at once, he's buying in small quantities almost every day. So I ask again: What's he up to? What does he know?

[Saskey]

11/3: And Shaw buys MORE. Three days in a row. Added to the days before. What's he up to?

[elcheepo]

hmmmm... juicy

[Saskey]

10/31: More insider buying. Thomas Shaw buys again!

[Saskey]

10/30: MORE insider buying. Thomas Shaw has been filing Insider Buy forms all week long.

[ClayTrader]

* * $RVP Video Chart 10-26-17 * *

Link to Video - click here to watch the technical chart video

[ClayTrader]

* * $RVP * *

Link to Video- watch analysis by clicking HERE

[Saskey]

Insider buying. Thomas Shaw bought shares on Friday.

[elcheepo]

I hear RVP name change to RIP

[elcheepo]

Yawwnnn

[Enterprising Investor]

Retractable Technologies, Inc. Files Motions in Connection with Becton, Dickinson and Co. Judgment (9/15/17)

LITTLE ELM, Texas--(BUSINESS WIRE)--Retractable Technologies, Inc. (NYSE American: RVP), (“RTI”) reports that on September 13, 2017, it filed a Motion to Alter or Amend the Judgment issued by the United States District Court for the Eastern District of Texas on August 17, 2017 which had ordered that RTI take nothing in its suit against Becton, Dickinson and Co. (“BD”). Such Motion asked the Court to require BD to notify end users of the facts relating to syringes, as required by the original injunction in this case.

RTI additionally reports that on September 14, 2017, it filed a Notice of Appeal to the United States Court of Appeals for the Fifth Circuit relating to the August 17 judgment discussed above.

Retractable manufactures and markets VanishPoint® and Patient Safe® safety medical products and the EasyPoint® needle. The VanishPoint® syringe, blood collection, and IV catheter products are designed to prevent needlestick injuries and product reuse by retracting the needle directly from the patient, effectively reducing exposure to the contaminated needle. Patient Safe® syringes are uniquely designed to reduce the risk of bloodstream infections resulting from catheter hub contamination. The EasyPoint® is a retractable needle that can be used with luer lock syringes, luer slip syringes, and prefilled syringes to give injections. The EasyPoint® needle also can be used to aspirate fluids and for blood collection. Retractable's products are distributed by various specialty and general line distributors.

For more information on Retractable, visit its website at www.retractable.com.

http://www.businesswire.com/news/home/20170915005936/en/Retractable-Technologies-Files-Motions-Connection-Becton-Dickinson

[upper11]

Rvp pinch play starting
http://stockcharts.com/h-sc/ui